Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Phase I data on SLN-124 support ongoing evaluation in patients with thalassemia and MDS

May 19, 2021

Anti-BAFF therapy eradicates factor VIII inhibitors in hemophilia A

May 19, 2021

First patient dosed in phase I/II MAA-202 study of MarzAA

May 19, 2021

FDA approves Empaveli for PNH

May 17, 2021

FDA approves Ferriprox to treat transfusional iron overload due to sickle cell disease

May 3, 2021

European Commission approves Orladeyo for the prevention of HAE attacks

May 3, 2021

Hillhurst cleared by FDA to begin phase I study of HBI-002 for sickle cell disease

April 28, 2021

FDA removes clinical hold on uniQure's hemophilia B gene therapy program

April 27, 2021

Fulcrum Therapeutics' FTX-6058 could be a disease-modifying treatment for sickle cell disease

April 26, 2021

FDA places clinical hold on proposed phase II study of KVD-824

April 21, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...